glp 1 agonist vs sglt2 inhibitor GLP-1 receptor agonists and inhibitors: a couple at last? GLP-1RAs and SGLT2 Inhibitors Show
Description
Chin J Liver Dis 2021;13:46-53
The Food and Drug Administration (FDA) has approved Eli Lillys Foundayo (orforglipron), a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, which offers a noninjectable option for weight management
Sustained Impact Weight loss extended for most individuals, even months after discontinuing
Median reduction in MHD was significantly higher in the GLP-1-RA group (4 [10.5, 0.5] vs
doi: 10.1155/2014/538737 [DOI] [PMC free article] [PubMed] [Google Scholar] 72
That means going beyond prescriptions to build care plans that integrate nutrition and lifestyle counselingbefore, during, and after the active weight reduction phase
